Skip To Main Content
Chau Dang on Muck Rack

Chau Dang

As seen in: HuffPost, Nature, Wiley Online Library, MDPI, Scientific American, JAMA Network, Emerald Publishing, ONCOLOGY journal, The ASCO Post, OncLive and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Chau

Contact Chau, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A Telemedicine-Supported Home-Injection Model for Patients With Breast Cancer

|
By Charlotte Malling, Erin M. Bange, Anne Reiner, Simone Porter, Jaclyn Andronico, Stacy Wong, Diana E. Lake, Chau Dang, Jasmeet Singh, Sahil D. Doshi, Susan C. Chimonas, Gilad Kuperman, Fernanda Polubriaginof, Peter B. Stetson, Tiffany A. Traina, Rachel Sanford, Bobby Daly, Michael Morris, Deborah Schrag, Katherine S. Panageas, Katherine Marcinkowski, Kelly Bonenfant, Karin Budrock, Heidi Sadowsky, Melissa Lee-Teh
| JAMA Network Verified
A Telemedicine-Supported Home-Injection Model for Patients With Breast Cancer Supplement 1. eMethods. Patient and Clinician Measures eTable. Selected Qualitative Data eFigure. Participants’ Reports of Barriers to Home Injections for GnRHa Treatment Supplement 2. Figure 1. Flowchart of Participant Recruitment (opens in new tab) Figure 2. Flowchart of Home-Injection Completion (opens in new tab) Figure 3.
Open in Who Shared Issue with article?

Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer - npj Breast Cancer

|
By Nicholas Mai, Pedram Razavi, Anton Safonov, Chau Dang, Larry Norton, Mark E. Robson, Sarat Chandarlapaty
| Nature Verified
Abstract After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment strategy is commonplace in modern clinical practice; however, the available prospective data investigating this strategy have had inconclusive results.
Open in Who Shared Issue with article?

Report: 24th ASEAN Energy Business Forum (AEBF-24)

|
By Brian McFeeters, Logan Carnicelli, Chau Dang, Amb. Brian McFeeters
| usasean.org
Authored By: Brian McFeeters, Senior VP and Regional Managing Director, USABC In Collaboration With: USABC Member Companies & U.S. Govt. Participants in AEBF-24 Edited By: Logan Carnicelli and Chau Dang Overview The September 25-27 ASEAN Energy Business Forum (AEBF) in Vientiane, painted a challenging energy transition picture. Energy demand across ASEAN is projected to grow by 60% by 2040 and to double by 2050, as reported by the AEBF Knowledge Partner, Boston Consulting Group (BCG).
Open in Who Shared Issue with article?
See all 12 licensed articles (21 Total)